MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 Lyon, France,…
Categorie
Press Releases
MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update The Company received an upfront payment…
November 4, 2025
MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH…
November 3, 2025
MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving…
October 7, 2025
MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results from Phase 3 trial for…
September 17, 2025
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program…
July 28, 2025
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux Lyon, France, July 24, 2025 – 6:00pm CET –…
July 24, 2025
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
July 7, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe MaaT Pharma and…
July 2, 2025
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France, June 24, 2025 – 8:00pm…
June 24, 2025
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.